Knockdown of RARB2 identifies a dual role in cancer

Genes Chromosomes and Cancer

Volumn 50, Issue 9, 2011, Pages 700-714

  Pappas, Jane J ^a,b   Toulouse, André ^c   Basik, Mark ^d   Lévesque, Luc ^d   Bradley, W E C ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; NEURONAL APOPTOSIS INHIBITORY PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLONY FORMATION; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR PROMOTION;

EID: 79960161481     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20892     Document Type: Article

References (50)

1. Ayoub J, Jean-Francois R, Cormier Y, Meyer D, Ying Y, Major P, Desjardins C, Bradley WE. 1999. Placebo-controlled trial of 13-cis-retinoic acid activity on retinoic acid receptor-beta expression in a population at high risk: Implications for chemoprevention of lung cancer. J Clin Oncol 17: 3546-3552.
2. Bagnato A, Spinella F, Rosano L. 2008. The endothelin axis in cancer: The promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol 86: 473-484.
3. Balmer JE, Blomhoff R. 2002. Gene expression regulation by retinoic acid. J Lipid Res 43: 1773-1808.
4. Berard J, Laboune F, Mukuna M, Masse S, Kothary R, Bradley WE. 1996. Lung tumors in mice expressing an antisense RARbeta2 transgene. FASEB J 10: 1091-1097.
5. Bovenzi V, Momparler RL. 2001. Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol 48: 71-76.
6. Bovenzi V, Le NL, Cote S, Sinnett D, Momparler LF, Momparler RL. 1999. DNA methylation of retinoic acid receptor beta in breast cancer and possible therapeutic role of 5-aza-2'-deoxycytidine. Anticancer Drugs 10: 471-476.
7. Brown AJ. 2000. Mechanisms for the selective actions of vitamin D analogues. Curr Pharm Des 6: 701-716.
8. Chambon P. 1996. A decade of molecular biology of retinoic acid receptors. FASEB J 10: 940-954.
9. Chen Y, Kamat V, Dougherty ER, Bittner ML, Meltzer PS, Trent JM. 2002. Ratio statistics of gene expression levels and applications to microarray data analysis. Bioinformatics 18: 1207-1215.
10. Cote S, Momparler RL. 1997. Activation of the retinoic acid receptor beta gene by 5-aza-2'-deoxycytidine in human DLD-1 colon carcinoma cells. Anticancer Drugs 8: 56-61.
11. Cote S, Sinnett D, Momparler RL. 1998. Demethylation by 5-aza-2'-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells. Anticancer Drugs 9: 743-750.
12. Diehn M, Sherlock G, Binkley G, Jin H, Matese JC, Hernandez-Boussard T, Rees CA, Cherry JM, Botstein D, Brown PO, Alizadeh AA. 2003. SOURCE: A unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res 31: 219-223.
13. Gebert JF, Moghal N, Frangioni JV, Sugarbaker DJ, Neel BG. 1991. High frequency of retinoic acid receptor beta abnormalities in human lung cancer. Oncogene 6: 1859-1868.
14. Geradts J, Chen JY, Russell EK, Yankaskas JR, Nieves L, Minna JD. 1993. Human lung cancer cell lines exhibit resistance to retinoic acid treatment. Cell Growth Differ 4: 799-809.
15. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555-567.
16. Group TACPS. 1994. The alpha-tocopherol, beta-carotene lung cancer prevention study: Design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol 4: 1-10.
17. Houle B, Leduc F, Bradley WE. 1991. Implication of RARB in epidermoid (Squamous) lung cancer. Genes Chromosomes Cancer 3: 358-366.
18. Houle B, Rochette-Egly C, Bradley WE. 1993. Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells. Proc Natl Acad Sci U S A 90: 985-989.
19. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM. 2009. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69: 3382-3389.
20. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, Katz RL. 2009. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 7: 330-338.
21. Khuri FR, Lotan R, Kemp BL, Lippman SM, Wu H, Feng L, Lee JJ, Cooksley CS, Parr B, Chang E, Walsh GL, Lee JS, Hong WK, Xu XC. 2000. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol 18: 2798-2804.
22. Knudson AG. 2001. Two genetic hits (more or less) to cancer. Nat Rev Cancer 1: 157-162.
23. Knudson AG, Jr. 1971. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68: 820-823.
24. Koki AT, Khan NK, Woerner BM, Seibert K, Harmon JL, Dannenberg AJ, Soslow RA, Masferrer JL. 2002. Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: Evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers. Prostaglandins Leukot Essent Fatty Acids 66: 13-18.
25. Moghal N, Neel BG. 1995. Evidence for impaired retinoic acid receptor-thyroid hormone receptor AF-2 cofactor activity in human lung cancer. Mol Cell Biol 15: 3945-3959.
26. Moreb JS, Gabr A, Vartikar GR, Gowda S, Zucali JR, Mohuczy D. 2005. Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. J Pharmacol Exp Ther 312: 339-345.
27. Nakajoh M, Fukushima T, Suzuki T, Yamaya M, Nakayama K, Sekizawa K, Sasaki H. 2003. Retinoic acid inhibits elastase-induced injury in human lung epithelial cell lines. Am J Respir Cell Mol Biol 28: 296-304.
28. Naylor SL, Johnson BE, Minna JD, Sakaguchi AY. 1987. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 329: 451-454.
29. Nervi C, Vollberg TM, George MD, Zelent A, Chambon P, Jetten AM. 1991. Expression of nuclear retinoic acid receptors in normal tracheobronchial cells and in lung carcinoma cells. Exp Cell Res 195: 163-170.
30. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA, Zangemeister-Wittke U. 2000. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60: 2805-2809.
31. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Jr., Valanis B, Williams JH, Jr., Barnhart S, Cherniack MG, Brodkin CA, Hammar S. 1996. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 88: 1550-1559.
32. Pappas JJ, Toulouse A, Hébert J, Fetni R, Bradley WEC. 2008. Allelic methylation bias of the RARB2 tumor suppressor gene promoter in cancer. Genes Chromosomes Cancer 47: 978-993.
33. Poulain S, Evenou F, Carre MC, Corbel S, Vignaud JM, Martinet N. 2009a. Vitamin A/retinoids signalling in the human lung. Lung Cancer 66: 1-7.
34. Poulain S, Lacomme S, Battaglia-Hsu SF, du Manoir S, Brochin L, Vignaud JM, Martinet N. 2009b. Signalling with retinoids in the human lung: Validation of new tools for the expression study of retinoid receptors. BMC Cancer 9: 423.
35. Roman SD, Clarke CL, Hall RE, Alexander IE, Sutherland RL. 1992. Expression and regulation of retinoic acid receptors in human breast cancer cells. Cancer Res 52: 2236-2242.
36. Seewaldt VL, Caldwell LE, Johnson BS, Swisshelm K, Collins SJ, Tsai S. 1997. Inhibition of retinoic acid receptor function in normal human mammary epithelial cells results in increased cellular proliferation and inhibits the formation of a polarized epithelium in vitro. Exp Cell Res 236: 16-28.
37. Shen S, Kruyt FA, den Hertog J, van der Saag PT, Kruijer W. 1991. Mouse and human retinoic acid receptor beta 2 promoters: Sequence comparison and localization of retinoic acid responsiveness. DNA Seq 2: 111-119.
38. Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S, Sacchi N. 2000. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene 19: 1556-1563.
39. Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, Toma S, Nicolo G, Sacchi N. 2002. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res 62: 2455-2461.
40. Sladek NE. 1999. Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. Curr Pharm Des 5: 607-625.
41. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA. 2006. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 103: 2316-2321.
42. Stein CA. 1995. Does antisense exist? Nat Med 1: 1119-1121.
43. Swisshelm K, Ryan K, Lee X, Tsou HC, Peacocke M, Sager R. 1994. Down-regulation of retinoic acid receptor beta in mammary carcinoma cell lines and its up-regulation in senescing normal mammary epithelial cells. Cell Growth Differ 5: 133-141.
44. Toulouse A, Morin J, Dion PA, Houle B, Bradley WE. 2000. RARbeta2 specificity in mediating RA inhibition of growth of lung cancer-derived cells. Lung Cancer 28: 127-137.
45. Toulouse A, Loubeau M, Morin J, Pappas JJ, Wu J, Bradley WE. 2000. RARbeta involvement in enhancement of lung tumor cell immunogenicity revealed by array analysis. FASEB J 14: 1224-1232.
46. Viallet J, Liu C, Emond J, Tsao MS. 1994. Characterization of human bronchial epithelial cells immortalized by the E6 and E7 genes of human papillomavirus type 16. Exp Cell Res 212: 36-41.
47. Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, Gazdar AF. 2000. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 92: 1303-1307.
48. Whang-Peng J, Kao-Shan CS, Lee EC, Bunn PA, Carney DN, Gazdar AF, Minna JD. 1982. Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science 215: 181-182.
49. Widschwendter M, Berger J, Hermann M, Muller HM, Amberger A, Zeschnigk M, Widschwendter A, Abendstein B, Zeimet AG, Daxenbichler G, Marth C. 2000. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst 92: 826-832.
50. Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, Kurie JM, Hong WK, Lotan R. 1997. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: Implications for lung cancer development. J Natl Cancer Inst 89: 624-629.